Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells 11,581 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $38.92, for a total value of $450,732.52. Following the completion of the sale, the chief financial officer now owns 112,933 shares in the company, valued at $4,395,352.36. This represents a 9.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, January 13th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.44, for a total value of $283,039.64.
• On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.98, for a total value of $126,305.74.
• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.77, for a total value of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total value of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98.

Hims & Hers Health Stock Performance

HIMS stock opened at $42.52 on Friday. Hims & Hers Health, Inc. has a 1 year low of $9.14 and a 1 year high of $46.01. The firm has a market cap of $9.29 billion, a P/E ratio of 96.64 and a beta of 1.35. The stock has a 50-day simple moving average of $30.22 and a 200-day simple moving average of $23.27.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently modified their holdings of HIMS. Yong Rong HK Asset Management Ltd acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $41,104,000. Principal Financial Group Inc. grew its stake in shares of Hims & Hers Health by 370.3% in the fourth quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company’s stock valued at $33,024,000 after buying an additional 1,075,355 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after buying an additional 883,230 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $18,048,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Hims & Hers Health by 128.7% in the fourth quarter. Bank of New York Mellon Corp now owns 1,244,953 shares of the company’s stock valued at $30,103,000 after buying an additional 700,500 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent analyst reports. Canaccord Genuity Group increased their target price on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Needham & Company LLC increased their target price on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, January 6th. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Morgan Stanley initiated coverage on Hims & Hers Health in a research report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price on the stock. Finally, BTIG Research started coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and an average price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.